Four million doses of Johnson & Johnson single shot vaccine are shipped out less than a day after receiving FDA approval as new cases in the US hit 54,000 and daily deaths continue to fall to 1,049
- Four million doses of the new Johnson & Johnson have been shipped out and will be ready to be injected into people from Tuesday
- The jab by Johnson & Johnson was approved on Saturday and only requires a single shot compared to two jabs with both the Moderna and Pfizer injection
- J&J is to also trial its vaccines in newborns, teens and pregnant women
- Another 1,049 deaths were reported Sunday bringing total to 513,091 lives lost
- Daily case numbers are roughly where they were in October and well below the single-day record of about 300,000 infections set in early January
- Sunday’s figures show there are currently 47,352 people in hospital with virus
- This weekend was the first time in four months the figure had dipped below 50,000 hospitalizations
Nearly four million doses of the newest COVID-19 vaccine by Johnson & Johnson were shipped out on Sunday night and will begin to be delivered to states for injections starting on Tuesday.
The White House said the entire stockpile of the newly approved single-dose Johnson & Johnson vaccine went out immediately after being approved on Saturday.
J&J will deliver about 16 million more doses by the end of March and 100 million total by the end of June, but the distribution would be backloaded.
Another 1,049 deaths were reported Sunday bringing total to 513,091 lives lost
Daily case numbers are roughly where they were in October and well below the single-day record of about 300,000 infections set in early January
Four million doses of the new Johnson & Johnson have been shipped out and will be ready to be injected into people from Tuesday
Though the new shot is easier to administer and requires only one dose, the administration is not altering its distribution plans.
The White House is encouraging Americans to take the first dose available to them, regardless of manufacturer.
The Johnson & Johnson vaccine will sit alongside those already offered by Pfizer-BioNTech and Moderna.
On Sunday night it was revealed another 1,049 people had died from the disease bring the total to 513,091 lives lost across the United States.
There are still 47,352 people in hospital with the virus across the nation, however, this weekend was the first time since November the figure had dipped below 50,000 people hospitalized.
The numbers are sure to improve further in the coming weeks following the approval of a third vaccine to combat the coronavirus which was formally approved as of Saturday evening.
Although almost 50 million people have received one dose of the coronavirus vaccine, the latest coronavirus variant was discovered in New York City last week and another worrying version of the virus is said to be spreading through California.
‘Things are tenuous,’ Dr. Rochelle Walensky, the director of the Centers for Disease Control and Prevention, said on Friday. ‘Now is not the time to relax restrictions.’
On Sunday it was announced that Johnson & Johnson are planning to their vaccine on infants and even newborns, together with pregnant women and in people who have compromised immune systems.
Johnson & Johnson is to also trial its vaccines in newborns, teens and pregnant women
Bonnie Rybstein, aged 98, from Woodmere, New York got her Covid vaccines as a special pop-up vaccination site for Holocaust survivors and seniors
A senior celebrates after receiving a Covid-19 vaccination at a Covid-19 pop-up vaccination site in Lawrence, New York
The clinical trials will take place at Harvard’s Boston Children’s Hospital.
The Pfizer and Moderna vaccines which are now being given to adults, plan to gradually test them in younger age groups. Currently, children 12 and older are being tested.
Johnson & Johnson will first test its vaccine in children older than 12 and under 18, but also plans to immediately include a study involving newborns and teens.
The company then will test its vaccine in pregnant women, and finally in immunocompromised people.